<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274910</url>
  </required_header>
  <id_info>
    <org_study_id>5961</org_study_id>
    <nct_id>NCT01274910</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial</brief_title>
  <acronym>EFOPaKR-01</acronym>
  <official_title>Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, randomized, double blind, placebo control study. The
      aim of this study is to assess the effect of fish oil capsules on pain intensity and
      postoperative analgesics consumption in patients after knee replacement surgery.

      The study population will be adult are referred for knee replacement surgery due to
      osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome:

      Post surgical pain level and analgesics use

      Secondary outcomes:

        1. Pain levels and analgesic use at six weeks and 3 months after surgery

        2. ω3 incorporation into blood cell membranes(RBC)

        3. Stress and inflammation markers

        4. Rates of postoperative complications

      Study Procedure :

      Enrolled patient will be randomly divided into a control group and intеrvention group during
      preoperative clinic visit. Each patient will receive total 150 capsules (5 capsules per day)
      accordingly to randomized group.

      Patients in treatment group will receive Fish Oil capsules. Patients in control group will
      receive placebo capsules.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>10 weeks</time_frame>
    <description>Pain assessment of patients will be measured using visual analog scale (VAS) score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgetics use</measure>
    <time_frame>10 weeks</time_frame>
    <description>All analgetics drugs used by patient will be noted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood test. Concentration of circulated inflammatory markers (TNF-α,IL-1,IL-6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Acids Composition</measure>
    <time_frame>Day 1</time_frame>
    <description>ω3 incorporation into blood cell membranes(RBC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>Day 1</time_frame>
    <description>Cortisol levels in blood test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTH</measure>
    <time_frame>Day 1</time_frame>
    <description>ACTH levels in blood test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Fish oil group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)</intervention_name>
    <description>Patient will receive Fish Oil capsules (EPAX 6000 EE) .
Treatment: 5 capsules per day</description>
    <arm_group_label>Fish oil group</arm_group_label>
    <other_name>Caps.Omeguard Triomar 1000 mg SGC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Capsules (Placebo)</intervention_name>
    <description>Patient will receive capsules which not contain fish oil.
Treatment: 5 capsules per day</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are referred for knee replacement surgery due to osteoarthritis of the knee

          -  Exclusion Criteria:

               -  Use of steroids, NSAIDs two weeks before surgery, antidepression drugs,
                  antiepileptic drugs, coumadin

               -  Diabetic neuropathy

               -  Herpes-zoster/ post-herpetic neuralgia

               -  n-3 supplements use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Singer, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICU dep't, Rabin MC,Petah Tikva, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milana Grinev, RN, Study Coordinator</last_name>
    <role>Study Director</role>
    <affiliation>ICU dep't, Rabin MC, Petah Tikva, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Singer, Professor, MD</last_name>
    <phone>972-3-9376521</phone>
    <email>psinger@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milana Grinev, RN, Study Coordinator</last_name>
    <phone>972-3-9376521</phone>
    <email>milang@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center, Campus Beilinson</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Singer, Professor ,MD</last_name>
      <phone>972-39376521</phone>
      <email>psinger@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Milana Grinev, RN, Study Coordinator</last_name>
      <phone>972-39376521</phone>
      <email>milang@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Sigal Frishman, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Pierre singer</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Fish Oil</keyword>
  <keyword>Knee</keyword>
  <keyword>Analgetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

